Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1986 1
1989 2
1990 2
1991 1
1992 2
1993 2
1995 2
1996 3
1997 2
2000 2
2001 3
2002 3
2003 6
2004 3
2005 7
2006 5
2007 5
2008 4
2009 5
2010 5
2011 2
2012 2
2013 4
2014 1
2016 2
2017 2
2018 4
2019 2
2020 2
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M, Harter P, Heitz F, du Bois A. Bommert M, et al. Clin Oncol (R Coll Radiol). 2018 Aug;30(8):493-497. doi: 10.1016/j.clon.2018.04.006. Epub 2018 May 7. Clin Oncol (R Coll Radiol). 2018. PMID: 29743148 Review.
Cytoreductive surgery is an important column in the treatment of primary ovarian cancer. Surgical outcome is one of the most important prognostic factors and one of the few prognostic variables that can be influenced by therapists. Retrospective studies suggested th …
Cytoreductive surgery is an important column in the treatment of primary ovarian cancer. Surgical outcome is one of the most important pr …
Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP, Schilder RJ. Martin LP, et al. Semin Oncol. 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. Semin Oncol. 2009. PMID: 19332246 Review.
Management for these two groups has diverged in the last few years, as evidence accrues that the response to treatment and duration of treatment-free interval after completion of front-line therapy impacts the prognosis and the treatment choice for these patients. Recent r …
Management for these two groups has diverged in the last few years, as evidence accrues that the response to treatment and duration of treat …
Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa N, Emoto R, Matsui S, Kajiyama H. Yoshihara M, et al. Int J Clin Oncol. 2022 Oct;27(10):1660-1668. doi: 10.1007/s10147-022-02214-9. Epub 2022 Jul 30. Int J Clin Oncol. 2022. PMID: 35906336
CONCLUSION: RFI of 1 year or longer and negative ascites cytology in the initial surgery were identified as independent predictive factors for LTSROC....
CONCLUSION: RFI of 1 year or longer and negative ascites cytology in the initial surgery were identified as independent predictive fa …
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G. Nunes RL, et al. J Gynecol Oncol. 2023 May;34(3):e31. doi: 10.3802/jgo.2023.34.e31. Epub 2023 Jan 20. J Gynecol Oncol. 2023. PMID: 36731894 Free PMC article.
Of the patients with 2 lesions by PET/CT, 48 (92.3%) underwent complete SCS. The sensitivity, positive predictive value, negative predictive value, and accuracy of PET/CT for NRD were 85.7%, 92.3%, 33.3%, and 81.2%, respectively. ...The accuracy of the MSK criteria, …
Of the patients with 2 lesions by PET/CT, 48 (92.3%) underwent complete SCS. The sensitivity, positive predictive value, negative …
Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis.
Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Limei Z, et al. Int J Gynecol Cancer. 2013 May;23(4):598-607. doi: 10.1097/IGC.0b013e31828a183c. Int J Gynecol Cancer. 2013. PMID: 23502451 Review.
CONCLUSIONS: Positron emission tomography/computed tomography is a useful tool for predicting the diagnosis and restaging of suspected recurrent ovarian carcinoma....
CONCLUSIONS: Positron emission tomography/computed tomography is a useful tool for predicting the diagnosis and restaging of suspecte …
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B. Colomban O, et al. EBioMedicine. 2023 Mar;89:104477. doi: 10.1016/j.ebiom.2023.104477. Epub 2023 Feb 16. EBioMedicine. 2023. PMID: 36801617 Free PMC article.
Individual values of rucaparib-adjusted KELIM (KELIM-PARP) were estimated based on the longitudinal CA-125 kinetics during the first 100 treatment days, and then scored as favorable (KELIM-PARP 1.0) or unfavorable (KELIM-PARP <1.0). The prognostic value of KELIM-PARP re …
Individual values of rucaparib-adjusted KELIM (KELIM-PARP) were estimated based on the longitudinal CA-125 kinetics during the first 100 tre …
Hyperthermic intraperitoneal chemotherapy in locally advanced and recurrent ovarian carcinoma: surgical and oncological outcomes in the Indian public healthcare system.
Saikia J, Bansal B, Deo S, Kumar N, Kuppusamy R, Barua A, Ray MD. Saikia J, et al. Future Oncol. 2021 May;17(14):1761-1776. doi: 10.2217/fon-2020-0806. Epub 2021 Mar 17. Future Oncol. 2021. PMID: 33728945
High PCI score, completeness of cytoreduction and major morbidities were independent predictors of overall survival in multivariate analysis. Conclusion: The application of HIPEC in limited-resource settings is feasible with acceptable major morbidities. ...
High PCI score, completeness of cytoreduction and major morbidities were independent predictors of overall survival in multivariate a …
84 results